Personalized

Cell Therapy

begins with

You.

Spotlight

Aspen Neuroscience to Partner with Rune Labs and Emerald Innovations to Incorporate both Active and Passive Digital Health Monitoring in Trial Ready Cohort Screening Study

Aspen Neuroscience Announces FDA Clearance of Investigational New Drug Application for ANPD001, Autologous Cell Therapy for the Treatment of Parkinson’s Disease

Preclinical Safety and Efficacy Data for ANPD001 Presented by Dr. Andres Bratt-Leal at 2023 World Parkinson Congress in Barcelona

Aspen Neuroscience leverages stem cell biology and genomics for Parkinson disease.

We are the leading company providing a personalized cell therapy with the aim to safely turn the clock back on Parkinson’s disease.

We are leveraging our in-house stem cell biology and genomics platform to provide the world’s first autologous induced pluripotent stem cell (iPSC)-derived neuron replacement therapy for Parkinson’s Disease.

Technology

News & Media

Investor Relations

Careers

ABOUT US

Find out about our organization,mission, our leadership team, our board of directors and scientific advisors.

Learn More

OUR PIPELINE

We are developing autologous IPSC-derived cell replacement therapies, including autologous neuron therapies to help treat both idiopathic and genetically linked forms of Parkinson’s disease.

Learn More

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.